A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of CUG252 following
multiple ascending doses in participants with Systemic Lupus Erythematosus (SLE).